Internists, Endocrinologist (diabetes, hormones)
13 years of experience
Video profile
Accepting new patients
Medical City Dallas
7777 Forest Lane
Building C Suite 206
Dallas, TX 75230
(972) 566-7272
Locations and availability (1)

Education ?

Medical School
Medical University - Varna (1997)
Foreign school

Awards & Distinctions ?

Awards  
Patients' Choice Award (2008 - 2009)
Bridges to Excellence Recognition
Diabetes Care Recognition (2013 - 2015)
Level II

Affiliations ?

Dr. Kaloyanova is affiliated with 3 hospitals.

Hospital Affilations

Score

Rankings

  • Medical City Dallas Hospital
    7777 Forest Ln, Dallas, TX 75230
    • Currently 4 of 4 crosses
    Top 25%
  • North Central Medical Center
    4500 Medical Center Dr, McKinney, TX 75069
    • Currently 3 of 4 crosses
    Top 50%
  • Medical City
  • Publications & Research

    Dr. Kaloyanova has contributed to 2 publications.
    Title Insulin-based Versus Triple Oral Therapy for Newly Diagnosed Type 2 Diabetes: Which is Better?
    Date December 2009
    Journal Diabetes Care
    Excerpt

    Early use of insulin after diagnosis of type 2 diabetes is met with resistance because of associated weight gain, hypoglycemia, and fear of decreased compliance and quality of life (QoL).

    Title Insulin As Initial Therapy in Type 2 Diabetes: Effective, Safe, and Well Accepted.
    Date April 2008
    Journal Journal of Investigative Medicine : the Official Publication of the American Federation for Clinical Research
    Excerpt

    BACKGROUND: To achieve glycemic control in type 2 diabetes mellitus (T2DM), multiple oral agents are used in a stepwise approach, but long-term maintenance of normoglycemia is difficult to achieve, and, eventually, most patients require insulin. The aim of this study was to evaluate the feasibility, acceptability, and efficacy of insulin with metformin for newly diagnosed, treatment-naive patients with T2DM. METHODS: Eligible patients were started on insulin NovoLog 70/30 and metformin 1,000 mg twice daily. Biochemical evaluation was performed at baseline and at the end of the 3-month study. Patients were seen monthly to assess side effects and compliance and make insulin dose adjustments. Patient treatment satisfaction was evaluated at the end of the study. RESULTS: Of 63 patients, 92% completed the study. The hemoglobin A(1c) (HbA(1c)) decreased from 10.8 to 5.9% (p < .0001), and 100% of subjects achieved an HbA(1)c < 7%. Weight increased from 100.0 to 101.6 kg (p = .004) but was less than expected given that patients lost an average of 7.2 kg prior to diagnosis and achieved a reduction in HbA(1c) of 5%. The rate of hypoglycemia was low (1.5 episodes/patient-month). Ninety-seven percent of the patients were satisfied with their insulin treatment, and 88% were willing to continue insulin. Compliance was 96.5% with insulin and 95.1% with metformin. CONCLUSION: Outpatient initiation of insulin therapy at the time of diagnosis of T2DM is an effective, safe, and feasible strategy for rapidly lowering HbA(1c) levels to targets. Insulin was very well accepted by the patients, refuting the misconception of low satisfaction and acceptance of such treatment.


    Similar doctors nearby

    Dr. Renee Stock

    General Practice
    11 years experience
    Dallas, TX

    Dr. Daniel Mijares

    Internal Medicine
    11 years experience
    Dallas, TX

    Dr. Afsaneh Ighani

    General Practice
    14 years experience
    Dallas, TX

    Dr. Oren Zebaida

    General Practice
    12 years experience
    Dallas, TX

    Dr. Shalaun Hawkins

    General Practice
    9 years experience
    Dallas, TX

    Dr. Cynthia Swayze Smith

    Internal Medicine
    11 years experience
    Dallas, TX
    Search All Similar Doctors